Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus PONVORY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus PONVORY.
FINGOLIMOD HYDROCHLORIDE vs PONVORY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymphoid tissues, reducing peripheral blood lymphocyte count.
0.5 mg orally once daily
0.5 mg orally once daily, starting with a 7-day titration: Days 1-4: 0.25 mg once daily; Days 5-7: 0.5 mg once daily. Maintenance: 0.5 mg once daily thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Terminal half-life is approximately 11 days (range 8-15 days), supporting once-daily dosing with steady-state reached in about 6-8 weeks.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Primarily metabolized via CYP3A4; elimination mainly as metabolites in feces (85-90%) and urine (<1% unchanged).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator